MedTrace Logo

Rebamipide in Patients With Active Rheumatoid Arthritis

NCT05166304 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-11-20

No results posted yet for this study

Summary

Although the aetiology of RA remains to be fully elucidated, interleukin (IL)-17 are believed to play a critical role in the pathogenesis of RA. Rebamipide is an antiulcer drug that protects gastric epithelial cells,improves gastric defense mechanisms by increasing gastric mucus. Rebamipide inhibited interleukin (IL)-17, also it inhibits IL-1β-induced RASF proliferation.

Conditions

Interventions

DRUG

Rebamipide

patients will receive the standard therapy plus 100 mg Rebamipide three times daily

DRUG

Placebo

patients will receive the standard therapy (methotrexate) plus placebo tablets

Sponsors & Collaborators

  • Minia University, faculty of medicine

    collaborator UNKNOWN

  • Sohag University

    collaborator OTHER

  • October 6 University

    lead OTHER

Principal Investigators

  • Esraa Abdallah · Minia University

  • Engy Wahsh · October 6 University

  • Asmaa Elsayed · Sohag University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-08-01
Completion
2025-09-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05166304 on ClinicalTrials.gov